Szebeni János, Fülöp Tamás, Dézsi László, Metselaar Bart, Storm Gert
a Nanomedicine Research and Education Center , Department of Pathophysiology, Semmelweis University , Budapest , Hungary.
b Department of Nanobiotechnology , Miskolc University , Miskolc , Hungary.
J Drug Target. 2016 Nov;24(9):765-767. doi: 10.3109/1061186X.2016.1172591. Epub 2016 Apr 27.
There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be "not-so-ugly", but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.
有直接和间接迹象表明，聚乙二醇化脂质体阿霉素（多美素），一种广泛使用的抗癌纳米药物，具有亚临床免疫抑制作用。作为一个看似不良的药理学特性结果却“没那么糟糕”，反而实际上有益的例子，作者强调了多美素免疫抑制作用的潜在益处。这些益处包括：（1）巨噬细胞系统对药物摄取的减少，这可能导致肿瘤摄取增加，从而提高治疗效果；（2）采用缓慢输注方案以降低超敏（输注）反应的风险；以及（3）可能预防对共同给药的反应原性药物的超敏反应。将免疫抑制视为有益的观点代表了纳米毒理学和抗癌化疗领域的范式转变。
